LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Kodu・Aktsiate loetelu・Coherus Oncology Inc

Coherus Oncology Inc

Suletud

SektorTervishoid

1.41 -0.7

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.41

Max

1.48

Põhinäitajad
By Trading Economics
Sissetulek	-278M -37M
Müük	-438K 12M
P/E Sektori keskmine	3.509 49.052
Aktsiakasum	-0.25
Kasumimarginaal	-300.041
Töötajad	145
EBITDA	7.9M -35M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+480.99% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-40M 219M
Eelmine avamishind	2.11
Eelmine sulgemishind	1.41

Uudiste sentiment

By Acuity

100%

315 / 344 Pingereas Healthcare

Coherus Oncology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. juuni 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9. juuni 2026, 23:45 UTC

Omandamised, ülevõtmised, äriostud

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9. juuni 2026, 23:44 UTC

Omandamised, ülevõtmised, äriostud

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9. juuni 2026, 23:44 UTC

Omandamised, ülevõtmised, äriostud

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9. juuni 2026, 23:43 UTC

Omandamised, ülevõtmised, äriostud

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9. juuni 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9. juuni 2026, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9. juuni 2026, 22:05 UTC

Omandamised, ülevõtmised, äriostud

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9. juuni 2026, 22:05 UTC

Omandamised, ülevõtmised, äriostud

Samsung: Additional Investment Makes It Largest Shareholder in Element

9. juuni 2026, 22:05 UTC

Omandamised, ülevõtmised, äriostud

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9. juuni 2026, 20:51 UTC

Tulu

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9. juuni 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. juuni 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9. juuni 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9. juuni 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9. juuni 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9. juuni 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9. juuni 2026, 18:52 UTC

Omandamised, ülevõtmised, äriostud

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9. juuni 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9. juuni 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9. juuni 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9. juuni 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9. juuni 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9. juuni 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9. juuni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9. juuni 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. juuni 2026, 16:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

9. juuni 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9. juuni 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Coherus Oncology Inc Prognoos

Hinnasiht

By TipRanks

480.99% tõus

12 kuu keskmine prognoos

Keskmine 8.25 USD 480.99%

Kõrge 12 USD

Madal 4 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Coherus Oncology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Coherus Oncology Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

315 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.